Meves Pharmaceuticals' Unattributed VC Round

Meves Pharmaceuticals raised a round of funding on March 29, 2018.

Meves Pharmaceuticals is developing nucleoside based therapies for mitochondrial DNA (mtDNA) depletion syndromes (MDS or MDDS), a category of severe genetic diseases. The initial focus is on therapy t…

Articles about Meves Pharmaceuticals' Unattributed VC Round: